

SUPPLEMENTARY DATA

Supplementary Figure 1. Likert scale questions relating to the general care of haemophilia patients with inhibitors: response distribution

Footnotes:

A total of 41 participants answered questions on general care in Round 1, and 34 in Round 2. Where questions did not achieve consensus in Round 1 and were carried forward to Round 2, only the Round 2 results are shown here. [a] Rephrased from question in Round 1; [b] New question added based on free-text response in Round 1; [c] Round 1 question restated in Round 2. ITI: immune tolerance induction.

Supplementary Figure 2. Likert scale questions relating to the care of adults only: response distribution

Footnotes:

A total of 25 participants answered questions on care of adults in Round 1, and 20 in Round 2. Where questions did not achieve consensus in Round 1 and were carried forward to Round 2, only the Round 2 results are shown here. [a] Rephrased from question in Round 1; [b] Round 1 question restated in Round 2; [c] New question added based on free-text response in Round 1. ITI: immune tolerance induction.

Supplementary Figure 3. Likert scale questions relating to the care of children/adolescents only: response distribution

Footnotes:

A total of 24 participants answered questions on paediatric care in Round 1, and 22 in Round 2. Where questions did not achieve consensus in Round 1 and were carried forward to Round 2, only the Round 2 results are shown here. One participant answered the 'adult

care only' questions in Round 1 but answered questions relating to the care of both children/adolescents and adults in Round 2. For consistency with Round 1, this participant's Round 2 child-related responses were not included in analyses. [a] Rephrased from question in Round 1; [b] New question added based on free-text response in Round 1. ITI: immune tolerance induction.

Supplementary Table 1. Targeted literature review strategy

Footnotes:

Guidelines published before May 2017 were included. National Guideline Clearinghouse website is no longer available online (as of 18th July 2018). [a] Searched using the 'Guidelines' option. [b] No search function was available therefore all guidelines on this website were searched by hand. BMJ: British Medical Journal; UKHCDO: United Kingdom Haemophilia Centre Doctors' Organisation; NA: not applicable; NHF: National HealthFormulary; MASAC: Medical and Scientific Advisory Council; NICE: National Institute for Health and Care Excellence.

Supplementary Table 2. Guidelines identified in the targeted literature review

Footnotes:

AHCDO: Australian Haemophilia Centre Directors' Organisation; FVIII: factor VIII; FIX: factor IX; ISTH: International Society on Thrombosis and Haemostasis; NHF: National Health Formulary; NHS: National Health Service; MASAC: Medical and Scientific Advisory Council; SSC: Scientific and Standardisation Committee; UKHCDO: United Kingdom Haemophilia Centre Doctors' Organisation.

Supplementary Table 3. Summary of Delphi panel questions on clinical goals

Supplementary Table 4. Summary of Delphi panel questions on the role of immune tolerance induction

Supplementary Table 5. Summary of Delphi panel questions on bypassing agents

Supplementary Table 6. Summary of Delphi panel questions on prophylaxis

Supplementary Table 7. Summary of Delphi panel questions on patients with mild or moderate haemophilia

Supplementary Information 1. Round 1 SurveyMonkey®questionnaire

Supplementary Information 2. Round 2 SurveyMonkey®questionnaire